VIDEO: CHAARTED 2 examines combination therapy for patients previously on docetaxel
Click Here to Manage Email Alerts
In this video, Alexander Chehrazi-Raffle, MD, discusses the results of the CHAARTED 2 cooperative group studies into metastatic castration-resistant prostate cancer, presented at ASCO Annual Meeting.
Chehrazi-Raffle, a medical oncologist at the City of Hope Duarte Cancer Center, discussed the study, which studied cabazitaxel plus abiraterone versus abiraterone alone in patients who had previously progressed on docetaxel.
“The big takeaway from CHAARTED 2 was that the combination of abiraterone plus cabazitaxel is worth exploring as an alternative to [androgen receptor pathway inhibitors] plus docetaxel for a high-volume hormone-sensitive prostate cancer, because that combination may afford a bit better efficacy compared to the docetaxel plus abiraterone or docetaxel plus thalidomide options that are currently helpful,” Chehrazi-Raffle said.
Collapse
Click Here to Manage Email Alerts